An interventional study of Lung Master (Pulmonary Exerciser) in Dyspnea, Chronic Obstructive Pulmonary Disease and Asthma, sponsored by University of Nebraska. Recruiting at 1 site in United States. Open to participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by University of Nebraska · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 214 studies in Dyspnea with a site in United States — 31 open to participants now, 37 under way, 1 of them phase 3. Dyspnea · United States.
Among the 214 studies in Dyspnea with a site in United States, this one is the 103rd largest by planned enrollment of the 151 interventional ones that give a count, is one of 13 that started in 2024, is one of 84 with no phase, reaches primary completion later than 14 of the 36 other live ones, and was the 189th registered.
895 studies on the registry are indexed under Dyspnea; 189 are open to participants now.
Browse Dyspnea studies →31 of the 214 studies in Dyspnea with a site in United States are open now. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18–75 · Healthy volunteers
Pfizer · Sites in United States
Ages 18+
Hackensack Meridian Health · Sites in United States
Ages 27 wk–34 wk
Joseph C. Wu · Sites in United States
Ages 40+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 125 Dyspnea studies recruiting now, 68 (54%) set no upper age limit and 41 (33%) stop at 75 or younger; 18 take children under 18; 23 take healthy volunteers.
This study: 19 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
214 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 40 · Phase 3 16 · Phase 4 12
First in 1999; this study’s year is marked. 13 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 50 across 588 interventional studies indexed under Dyspnea.
Median enrollment 36 across the 151 interventional studies, 93 across the 62 observational. Of the 162 that completed or were terminated, 56 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
53 of 214 have an industry lead sponsor. The 10 most frequent:
University of Nebraska is the lead sponsor of 496 studies on the registry; 66 are open to participants now.
Of its 83 completed or terminated interventional studies of FDA-regulated products, 53 (64%) have results posted.
University of Nebraska has 3 studies filed under Dyspnea — fewer than ten, so there is no comparison to draw.
13 of the studies in Dyspnea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05866952Tufts Medical CenterVentilatory and Perfusion Abnormalities in Individuals With Post-Acute Sequelae of SARS-CoV-2 Infection | 2026-12 |
| NCT07386444Ohio State University Comprehensive Cancer CenterInspiratory Muscle Training for Breast Cancer Patients on Chemotherapy | 2026-12-31 |
| NCT06684119Children's Hospital Los AngelesPediatric Positive End Expiratory Pressure (PEEP) Titration Using Electrical Impedence Tomography (EIT) | 2027-01-01 |
| NCT06524856University of NebraskaThe Increase of Lung Capacity Using the Lung Master (Pulmonary Exerciser) | 2027-03-01 |
| NCT06977581PfizerA Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | 2027-03-08 |
Add all 13 to your calendar (.ics) → With an account.
Among the 214 studies in Dyspnea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Investigators are studying how a device called The Lung Master device can help people breathe better. The investigational device increases the amount of air our lungs can hold, which is important for overall lung health. The Lung Master is not approved by the FDA.
The study has two visits approximately one month apart. In the first visit participants will take a spirometry test, particularly forced vital capacity (FVC), to measure volume change in the lungs. Participants will take the investigational device home to use daily, either in the morning or evening. Use will be recorded in a diary. After one month, participants will return for another spirometry test. Each study visit will take about one to two hours to complete.
Shortness of breath,or dyspnea, occurs when the lungs do not receive enough oxygen leading to discomfort when breathing. This occurs in a quarter of individuals seen in an outpatient setting. Several factors can relate to breathlessness, including lung disorders, heart conditions, or stress. Patients with breathlessness often experience physical limitations in their daily activities. Various treatments for dyspnea are available, however, chronic breathlessness syndrome, such as asthma or chronic obstructive pulmonary disease (COPD), still can persist even when treatment is available.
The Lung Master (Pulmonary Exerciser) is a breathing device used for the respiratory treatment and rehabilitation of chronic breathlessness syndrome. The Lung Master increases resistance during inhalation and exhalation, which works to strengthen the respiratory muscle and improve overall lung function. Therefore, this study will focus on determining how the Lung Master increases lung capacity in healthy individuals. The device is considered investigational and has not been approved by the FDA.
Two groups of healthy participants will be sought for the study: ages 19 to 35 and ages 65 and above. Each participant will have two in-office study visits approximately one month apart. Each visit will take around one to two hours to complete. At the visits, a breathing test called a spirometry test will be done. During the one month interim, the study device will be used at home and the use recorded in a diary. The device must be used least once every day, either in the morning or in the evening for 5 to 20 minutes. You will be contacted after two weeks, and then return the device at the second study visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Lung functions will be assess for two groups: young and older adults. The age range of 19 to 35 is categorized as young adulthood. This age range was selected because the lungs mature around 19-25 years old. The age range above 65 is designated as late adulthood, where lung function gradually declines.
Device: Lung Master (Pulmonary Exerciser)
During the one-month using the Lung Master at their house, the participant will be using it at least one time every day, either in the morning or in the evening before going to sleep. During the session, the participants will sit upright and try to prolong the inhalation and exhalation breaths through the Lung Master device for at least three seconds. For each session, the participants will try to concentrate on 35-50 breaths in and breaths out which is about 2-5 minutes. Every session can involve using the Pulmonary Exerciser for a minimum of 5 minutes and a maximum of 20 minutes. After each session, participants will be asked to note how long they have used the device and when they have used it. Information from each session will be recorded on the Participant Device Log that will be provided.
Inspiratory Capacity
After reaching the end of a normal, quiet expiration, the maximum volume of air that can be inspired will be measured.
Time frame: baseline and after one month of device use
Tidal Volume
The amount of air that moves in or out of the lungs with each respiratory cycle will be measured.
Time frame: baseline and after one month of device use
Plan to share: No
Started Oct 2024 (actual). Primary completion is estimated for Mar 2027, 29 months after the start.
Of 268 non-industry interventional studies with no phase under Dyspnea, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 29 months is above that.
Counting every sponsor, half of 284 studies reached it within 13 months; a quarter within 6 and three quarters within 29.
Completion moved once since we started tracking on Sep 25, 2026: Mar 2027 → Mar 2029, on Oct 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.